Lupus
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
EULAR 2021 opened with a grand debate to answer this essential question: should clinicians treat to remission or to Lupus Low Disease Activity State (LLDAS)?

Dr. John Cush RheumNow
4 years ago
Promising options to treat mucocutaneous disease in SLE #EULAR2021
https://t.co/JoChBNRfqu https://t.co/6jjhuEOQgO


Dr. John Cush RheumNow
4 years ago
Video: Combination DMARD for Lupus Nephritis: Dr. Kathryn Dao ( @KDAO2011 )
#EULAR2021
https://t.co/RGVZ6jukYy https://t.co/PTjSOfM7YQ

An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351).
Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response.
Cutaneous lupus erythematosus (CLE) consists of a wide range of dermatologic manifestations seen in people with or without systemic lupus erythematosus (SLE). CLE can be categorised into LE-specific lesions, i.e. acute CLE (ACLE), subacute CLE (SCLE) and chronic CLE (CCLE), and nonspecific LE skin lesions (e.g. vasculitis).

Dr. John Cush RheumNow
4 years ago
Current approach to lupus and pregnancy by Dr. Robert Chao ( @doctorRBC) #EULAR2021
https://t.co/eFd6j9YZo5 https://t.co/tW9tJIRpjm


Dr. John Cush RheumNow
4 years ago
#EULAR2021 - Day 3 Report
https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has provided much-needed reassuring answers.

Dr. John Cush RheumNow
4 years ago
Video: IFN Scores Predict Resistance to Skin Disease During RTX Therapy in Lupus
Dr. Yuz Yusof speaks with Dr. Lucy Carter about abstract OP0134, presented at the virtual #EULAR2021 meeting.
https://t.co/pqr8uRBiRG https://t.co/lhvuYIfI34


Dr. John Cush RheumNow
4 years ago
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 )
Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021.
https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU
